UNLABELLED: Fibroblast growth factor (FGF) signaling and beta-catenin activation have been shown to be crucial for early embryonic liver development. This study determined the significance of FGF10-mediated signaling in a murine embryonic liver progenitor cell population as well as its relation to beta-catenin activation. We observed that Fgf10(-/-) and Fgfr2b(-/-) mouse embryonic livers are smaller than wild-type livers; Fgf10(-/-) livers exhibit diminished proliferation of hepatoblasts. A comparison of beta-galactosidase activity as a readout of Fgf10 expression in Fgf10(+/LacZ) mice and of beta-catenin activation in TOPGAL mice, demonstrated peak Fgf10 expression from E9 to E13.5 coinciding with peak beta-catenin activation. Flow cytometric isolation and marker gene expression analysis of LacZ(+) cells from E13.5 Fgf10(+/LacZ) and TOPGAL livers, respectively, revealed that Fgf10 expression and beta-catenin signaling occur distinctly in stellate/myofibroblastic cells and hepatoblasts, respectively. Moreover, hepatoblasts express Fgfr2b, which strongly suggests they can respond to recombinant FGF10 produced by stellate cells. Fgfr2b(-/-)/TOPGAL(+/+) embryonic livers displayed less beta-galactosidase activity than livers of Fgfr2b(+/+)/TOPGAL(+/+) littermates. In addition, cultures of whole liver explants in Matrigel or cell in suspension from E12.5 TOPGAL(+/+)mice displayed a marked increase in beta-galactosidase activity and cell survival upon treatment with recombinant FGF10, indicating that FGFR (most likely FGFR2B) activation is upstream of beta-catenin signaling and promote hepatoblast survival. CONCLUSION: Embryonic stellate/myofibroblastic cells promote beta-catenin activation in and survival of hepatoblasts via FGF10-mediated signaling. We suggest a role for stellate/myofibroblastic FGF10 within the liver stem cell niche in supporting the proliferating hepatoblast.
UNLABELLED: Fibroblast growth factor (FGF) signaling and beta-catenin activation have been shown to be crucial for early embryonic liver development. This study determined the significance of FGF10-mediated signaling in a murine embryonic liver progenitor cell population as well as its relation to beta-catenin activation. We observed that Fgf10(-/-) and Fgfr2b(-/-) mouse embryonic livers are smaller than wild-type livers; Fgf10(-/-) livers exhibit diminished proliferation of hepatoblasts. A comparison of beta-galactosidase activity as a readout of Fgf10 expression in Fgf10(+/LacZ) mice and of beta-catenin activation in TOPGAL mice, demonstrated peak Fgf10 expression from E9 to E13.5 coinciding with peak beta-catenin activation. Flow cytometric isolation and marker gene expression analysis of LacZ(+) cells from E13.5 Fgf10(+/LacZ) and TOPGAL livers, respectively, revealed that Fgf10 expression and beta-catenin signaling occur distinctly in stellate/myofibroblastic cells and hepatoblasts, respectively. Moreover, hepatoblasts express Fgfr2b, which strongly suggests they can respond to recombinant FGF10 produced by stellate cells. Fgfr2b(-/-)/TOPGAL(+/+) embryonic livers displayed less beta-galactosidase activity than livers of Fgfr2b(+/+)/TOPGAL(+/+) littermates. In addition, cultures of whole liver explants in Matrigel or cell in suspension from E12.5 TOPGAL(+/+)mice displayed a marked increase in beta-galactosidase activity and cell survival upon treatment with recombinant FGF10, indicating that FGFR (most likely FGFR2B) activation is upstream of beta-catenin signaling and promote hepatoblast survival. CONCLUSION: Embryonic stellate/myofibroblastic cells promote beta-catenin activation in and survival of hepatoblasts via FGF10-mediated signaling. We suggest a role for stellate/myofibroblastic FGF10 within the liver stem cell niche in supporting the proliferating hepatoblast.
Authors: Heike Steiling; Torsten Wüstefeld; Philippe Bugnon; Maria Brauchle; Reinhard Fässler; Daniel Teupser; Joachim Thiery; Jeffrey I Gordon; Christian Trautwein; Sabine Werner Journal: Oncogene Date: 2003-07-10 Impact factor: 9.867
Authors: Satdarshan P S Monga; Wendy M Mars; Peter Pediaditakis; Aaron Bell; Karen Mulé; William C Bowen; Xue Wang; Reza Zarnegar; George K Michalopoulos Journal: Cancer Res Date: 2002-04-01 Impact factor: 12.701
Authors: Anan Abu Rmilah; Wei Zhou; Erek Nelson; Li Lin; Bruce Amiot; Scott L Nyberg Journal: Wiley Interdiscip Rev Dev Biol Date: 2019-03-28 Impact factor: 5.814
Authors: Nirmala Mavila; David James; Pranavkumar Shivakumar; Marie V Nguyen; Sarah Utley; Katrina Mak; Allison Wu; Shengmei Zhou; Larry Wang; Christopher Vendyres; Megan Groff; Kinji Asahina; Kasper S Wang Journal: Hepatology Date: 2014-07-17 Impact factor: 17.425
Authors: Tove Berg; Stijn DeLanghe; Denise Al Alam; Sarah Utley; Joaquin Estrada; Kasper S Wang Journal: J Surg Res Date: 2009-11-14 Impact factor: 2.192
Authors: Sarah Utley; David James; Nirmala Mavila; Marie V Nguyen; Christopher Vendryes; S Michael Salisbury; Jennifer Phan; Kasper S Wang Journal: J Hepatol Date: 2013-12-21 Impact factor: 25.083
Authors: Kinji Asahina; Shirley Y Tsai; Peng Li; Mamoru Ishii; Robert E Maxson; Henry M Sucov; Hidekazu Tsukamoto Journal: Hepatology Date: 2009-03 Impact factor: 17.425